Frontier IP Group Plc (FIPP.L) Announced with respect to the announcement from portfolio company Exscientia, a world leader in artificial intelligence (AI) drug discovery, that it has achieved its first major milestone in its collaboration with GSK. Exscientia has delivered a lead molecule targeting chronic obstructive pulmonary disease (COPD), a progressive lung disease thought to affect 384 million people globally. The company holds a 3.32% stake in Exscientia.
Login or register to post comments